Table 3 Sensitivity and specificity for emerging but not yet accredited laboratory tests
From: Lyme borreliosis diagnosis: state of the art of improvements and innovations
Classification | Tests | Sensitivity | Specificity | References |
|---|---|---|---|---|
Microfluidics, lateral and vertical flow immunoassay | mChip-Ld | 84% | 92% | [75] |
Lyme IgM and IgG | 26% | 85% | [70] | |
Keul-o-test Borreliose Complete IgM and IgG test | 32% | 88% | ||
ReaScan + C6 LYME IgG | 83% | 91% | [71] | |
Multiplexed vertical flow assay (xVFA) | 86% | 96% | [73] | |
Luminex | Paramagnetic bead-based multiplex assay and INTELLIFLEX System | 94% | 97% | [74] |
ELISpot and cells-based approaches | iSpot LymeTM | 54—84% | 54 – 94% | |
QuantiFERON-Lyme | 70% | na | [78] | |
Spirofind | 43% | 82% | [77] | |
LTT-MELISA | 30% | 53% | ||
TCR sequencing | 56% | 99% | [79] | |
Biomarkers detection | ReaScan CXCL13 assay | 78% | 95% | |
RecomBead CXCL13 assay | 86 – 100% | 91 – 97% | ||
Quantikine CXCL13 ELISA | 88 – 100% | 89 – 99% | ||
Metabolomics techniques | 88% | 95% | [83] | |
Raman Spectroscopy (RS) | SERS and DNA aptamers | 91% | 96% | [84] |
Raman Spectroscopy | 85% | 90% | [85] | |
Raman Spectroscopy & Chemometrics | 83% | 91% | [86] | |
PCR-based approaches | Immuno-PCR | 69% | 98% | [87] |